

GENENTECH INC  
Form SC 14D9/A  
March 12, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14D-9**

**Solicitation/Recommendation Statement**

**Under Section 14(d)(4) of the Securities Exchange Act of 1934**

**(Amendment No. 6)**

**GENENTECH, INC.**

*(Name of Subject Company)*

**GENENTECH, INC.**

*(Name of Person Filing Statement)*

**Common Stock, par value \$0.02 per share**

*(Title of Class of Securities)*

**368710406**

*(CUSIP Number of Class of Securities)*

**Sean A. Johnston**

**Genentech, Inc.**

**1 DNA Way**

**South San Francisco, California 94080-4990**

**(650) 225-1000**

*(Name, address and telephone number of person authorized to receive  
notices and communications on behalf of the persons filing statement)*

Edgar Filing: GENENTECH INC - Form SC 14D9/A

*With copies to:*

**Charles M. Nathan  
John M. Newell  
Latham & Watkins LLP  
885 Third Avenue  
New York, New York 10022-4834  
(212) 906-1200**

**Larry W. Sonsini  
Martin W. Korman  
Wilson Sonsini Goodrich & Rosati  
Professional Corporation  
650 Page Mill Road  
Palo Alto, California 94304  
(650) 493-9300**

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Amendment No. 6 to the Solicitation/Recommendation Statement on Schedule 14D-9 (the **Schedule 14D-9**) amends and supplements the Schedule 14D-9 originally filed by Genentech, Inc., a Delaware corporation (the **Company**), with the Securities and Exchange Commission (the **SEC**) on February 23, 2009, as amended, relating to the tender offer commenced by Roche Investments USA Inc. (**Roche Investments**) pursuant to which Roche Investments has offered to purchase all the outstanding Common Stock, par value \$0.02 per share (the **Shares**) of the Company not owned by Roche Holding Ltd (**Roche Holding**) and together with its affiliates (excluding the Company and its subsidiaries) and Roche Investments, **Roche**, upon the terms and conditions set forth in the Offer to Purchase dated February 9, 2009 and the related Letter of Transmittal (which together with the Offer to Purchase and any amendments or supplements thereto, collectively, constitute the **Offer**) contained in the Schedule TO filed by Roche Investments with the SEC on February 9, 2009, as amended (the **Schedule TO**). Capitalized terms used but not defined herein have the meaning ascribed to them in the Schedule 14D-9.

On March 12, 2009, the Company entered into an Agreement and Plan of Merger with Roche Holdings, Inc. and Roche Investments (the **Merger Agreement**) and related Guarantee by Roche Holding Ltd for the benefit of the Company (the **Guarantee**), pursuant to which Roche agreed to increase the Offer price to \$95.00 per Share (the **Revised Offer Price**) and to change certain other terms and conditions of the Offer (the **Revised Offer**) and the Special Committee agreed to recommend that the Company's stockholders, other than Roche and its affiliates, accept the Revised Offer and tender their Shares pursuant to the Revised Offer.

**Item 9. Exhibits.**

Item 9 is amended and supplemented by adding the following thereto:

(a)(12) Email from Art Levinson, dated March 11, 2009 to the Company's employees

(a)(13) Employee Q&A posted to the Company's intranet website on March 12, 2009

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

**GENENTECH, INC.**

By: /s/ Stephen G. Juelsgaard  
Name: Stephen G. Juelsgaard

Title: Executive Vice President, Secretary and  
Chief Compliance Officer

Dated: March 12, 2009